V-set and transmembrane domain containing 2BGenealiases: []
Q-omics provides the consensus-scored VSTM2B profile across patient tissues and cancer cell-line models. VSTM2B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, VSTM2B is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, VSTM2B RNA expression shows 13,372 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, STAD, and GBM as cancer lineages where VSTM2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VSTM2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VSTM2B survival associations across molecular data types. VSTM2B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VSTM2B RNA expression–survival associations across cancer types. High VSTM2B expression shows unfavorable associations in UCEC, UVM, KIRP, MESO, KIRC and ESCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for VSTM2B RNA expression.
This table summarizes VSTM2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for VSTM2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VSTM2B shows lower tumor expression in STAD and KIRP and higher tumor expression in LIHC. The STAD box plot shows higher VSTM2B RNA expression in normal versus tumor tissue (log2 FC = −0.184, t-test p = .006).
This table shows molecular features associated with VSTM2B in patient tissues and cancer cell lines. In patient samples, VSTM2B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, VSTM2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
